SG11201810420YA - Antibodies to alpha-synuclein and uses thereof - Google Patents
Antibodies to alpha-synuclein and uses thereofInfo
- Publication number
- SG11201810420YA SG11201810420YA SG11201810420YA SG11201810420YA SG11201810420YA SG 11201810420Y A SG11201810420Y A SG 11201810420YA SG 11201810420Y A SG11201810420Y A SG 11201810420YA SG 11201810420Y A SG11201810420Y A SG 11201810420YA SG 11201810420Y A SG11201810420Y A SG 11201810420YA
- Authority
- SG
- Singapore
- Prior art keywords
- synuclein
- international
- antibodies
- cambridge
- building
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344746P | 2016-06-02 | 2016-06-02 | |
| PCT/EP2017/063406 WO2017207739A1 (en) | 2016-06-02 | 2017-06-01 | Antibodies to alpha-synuclein and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810420YA true SG11201810420YA (en) | 2018-12-28 |
Family
ID=59021492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810420YA SG11201810420YA (en) | 2016-06-02 | 2017-06-01 | Antibodies to alpha-synuclein and uses thereof |
Country Status (37)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| BR112018014281A2 (pt) | 2016-11-15 | 2018-12-18 | H Lundbeck As | agentes, usos e métodos para o tratamento da sinucleinopatia |
| EP3555127B1 (en) | 2016-12-16 | 2024-12-18 | H. Lundbeck A/S | Agents, uses and methods |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| CA3051839A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| MX2021004454A (es) * | 2018-10-19 | 2021-07-07 | Janssen Vaccines & Prevention Bv | Anticuerpos anti-sinucleina. |
| TWI734279B (zh) | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| JP7689373B2 (ja) | 2019-04-18 | 2025-06-06 | エイシー イミューン ソシエテ アノニム | 治療及び診断のための新規分子 |
| CN110172098B (zh) * | 2019-05-27 | 2023-03-10 | 长春工业大学 | 抗α-突触核蛋白的单克隆抗体及其应用 |
| US20230074436A1 (en) | 2019-09-20 | 2023-03-09 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| KR102239512B1 (ko) * | 2020-09-10 | 2021-04-12 | 서울대학교산학협력단 | 다중기능성 마이크로캡슐 조성물 및 그 제조방법 |
| EP4229082A1 (en) | 2020-10-16 | 2023-08-23 | AC Immune SA | Antibodies binding to alpha-synuclein for therapy and diagnosis |
| CN112920274A (zh) * | 2021-03-17 | 2021-06-08 | 江苏贝格尔生物医药有限公司 | 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用 |
| CN113912716B (zh) * | 2021-12-15 | 2022-03-01 | 北京凯祥弘康生物科技有限公司 | 针对α-突触核蛋白抗原的抗体及其应用 |
| TW202440629A (zh) | 2022-12-29 | 2024-10-16 | 瑞典商阿斯特捷利康公司 | 用於治療α共核蛋白病(SYNUCLEINOPATHIES)之組合物及方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE414151T1 (de) | 2000-03-03 | 2008-11-15 | Cambridge Antibody Tech | Antikörper gegen eotaxin und deren verwendung |
| CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| PL2361928T3 (pl) | 2003-05-19 | 2017-09-29 | Prothena Biosciences Limited | Skrócone fragmenty alfa-synukleiny w chorobie z ciałami Lewy'ego |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| EA013752B1 (ru) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний |
| WO2007036022A1 (en) | 2005-09-27 | 2007-04-05 | National Research Council Of Canada | Targeted delivery of compounds using multimerization technology |
| PL2583978T3 (pl) * | 2007-02-23 | 2016-07-29 | Prothena Biosciences Ltd Co | Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| JP4934074B2 (ja) | 2007-03-07 | 2012-05-16 | 株式会社アルファ | スイッチ固定構造 |
| PT2282758T (pt) | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
| CN102317316B (zh) | 2008-12-19 | 2014-08-13 | 帕尼玛制药股份公司 | 人抗α突触核蛋白自身抗体 |
| JP4654348B1 (ja) | 2010-02-23 | 2011-03-16 | 多摩川精機株式会社 | 検出装置用巻線の正弦波巻線方法 |
| JP5894939B2 (ja) * | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| SI2723379T1 (sl) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| RS63930B1 (sr) | 2011-10-28 | 2023-02-28 | Prothena Biosciences Ltd | Humanizovana antitela koja prepoznaju alfa-sinuklein |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| LT3071597T (lt) * | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai |
| GB2537445A (en) | 2014-11-10 | 2016-10-19 | Medimmune Ltd | Binding molecules specific for CD73 and uses thereof |
-
2017
- 2017-06-01 US US15/611,416 patent/US10160800B2/en active Active
- 2017-06-01 EP EP21202106.7A patent/EP4000632A1/en active Pending
- 2017-06-01 SM SM20220008T patent/SMT202200008T1/it unknown
- 2017-06-01 RS RS20211502A patent/RS62682B1/sr unknown
- 2017-06-01 PE PE2023002924A patent/PE20250392A1/es unknown
- 2017-06-01 EP EP17728525.1A patent/EP3463435B1/en active Active
- 2017-06-01 AR ARP170101504A patent/AR108663A1/es unknown
- 2017-06-01 TW TW106118078A patent/TWI765890B/zh active
- 2017-06-01 GE GEAP201714964A patent/GEP20217253B/en unknown
- 2017-06-01 KR KR1020187037675A patent/KR102499438B1/ko active Active
- 2017-06-01 LT LTEPPCT/EP2017/063406T patent/LT3463435T/lt unknown
- 2017-06-01 GE GEAP202114964A patent/GEAP202114964A/en unknown
- 2017-06-01 PL PL17728525T patent/PL3463435T3/pl unknown
- 2017-06-01 CN CN201780045951.2A patent/CN109475616B/zh active Active
- 2017-06-01 UA UAA201811679A patent/UA124733C2/uk unknown
- 2017-06-01 JP JP2018563050A patent/JP7078552B2/ja active Active
- 2017-06-01 DK DK17728525.1T patent/DK3463435T3/da active
- 2017-06-01 ES ES17728525T patent/ES2903402T3/es active Active
- 2017-06-01 CA CA3025987A patent/CA3025987A1/en active Pending
- 2017-06-01 PE PE2018003155A patent/PE20190440A1/es unknown
- 2017-06-01 MX MX2018014456A patent/MX393740B/es unknown
- 2017-06-01 MY MYPI2018002168A patent/MY188183A/en unknown
- 2017-06-01 EA EA202191380A patent/EA202191380A1/ru unknown
- 2017-06-01 HU HUE17728525A patent/HUE057214T2/hu unknown
- 2017-06-01 WO PCT/EP2017/063406 patent/WO2017207739A1/en not_active Ceased
- 2017-06-01 AU AU2017272804A patent/AU2017272804B2/en active Active
- 2017-06-01 EA EA201892548A patent/EA038358B1/ru unknown
- 2017-06-01 SI SI201731025T patent/SI3463435T1/sl unknown
- 2017-06-01 BR BR112018074978-8A patent/BR112018074978A2/pt active Search and Examination
- 2017-06-01 SG SG11201810420YA patent/SG11201810420YA/en unknown
- 2017-06-01 MA MA45125A patent/MA45125B1/fr unknown
- 2017-06-01 CN CN202211223767.1A patent/CN116120445A/zh active Pending
- 2017-06-01 MD MDE20190406T patent/MD3463435T2/ro unknown
- 2017-06-01 TW TW111117603A patent/TW202309093A/zh unknown
- 2017-06-01 HR HRP20211935TT patent/HRP20211935T1/hr unknown
- 2017-06-01 PT PT177285251T patent/PT3463435T/pt unknown
-
2018
- 2018-10-25 US US16/170,468 patent/US10889639B2/en active Active
- 2018-11-22 IL IL263243A patent/IL263243A/en unknown
- 2018-11-29 PH PH12018502538A patent/PH12018502538A1/en unknown
- 2018-11-30 CL CL2018003438A patent/CL2018003438A1/es unknown
- 2018-12-19 ZA ZA2018/08582A patent/ZA201808582B/en unknown
- 2018-12-21 CO CONC2018/0014010A patent/CO2018014010A2/es unknown
- 2018-12-28 EC ECSENADI201896095A patent/ECSP18096095A/es unknown
-
2020
- 2020-12-03 US US17/111,159 patent/US11560424B2/en active Active
-
2022
- 2022-01-05 CY CY20221100010T patent/CY1124896T1/el unknown
- 2022-05-19 JP JP2022082099A patent/JP2022110117A/ja active Pending
-
2023
- 2023-01-20 US US18/099,671 patent/US20230331830A1/en active Pending
-
2024
- 2024-01-31 AU AU2024200601A patent/AU2024200601A1/en active Pending
- 2024-06-27 JP JP2024103562A patent/JP7823118B2/ja active Active
-
2025
- 2025-01-16 US US19/025,554 patent/US20250263477A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201900596XA (en) | Cannabis composition | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
| SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201906557UA (en) | Novel stable formulation for fxia antibodies | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof |